Study: NCT04207112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Drugs
Description: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.